vialroom

#retatrutide 2025-12-19

Friday32 messages6 participantstimes are UTC
Highlights from this day
  • vialkeeper — how slow is low and slow here, four weeks a step or longer 17:43
  • tail_factor — did anyone come off because of the heart rate 17:45
  • oasis_ola — research use only is on every vial and i treat it as exactly that, nobody here is prescribing 18:23
  • holly_holds — quick one TRIUMPH is the phase 3 programme, thats the name to search rather than the molecule 19:53

how slow is low and slow here, four weeks a step or longer

🧪1👍1🙏7

is the GI worse than tirzepatide or about the same

VI

my resting rate went up 4 bpm in the first month and came back most of the way by month 1
the purity spread across lots worries me more than the molecule does

no long term data

🔥3🤝6

blood pressure stayed flat for me while heart rate moved, which i didnt expect

phase 2 was still trending at the end which is why the phase 3 readout matters more than usual

glucagon is the new bit

OO

no idea whether the heart rate settles for everyone, mine did and one log isnt data

OO

research use only is on every vial and i treat it as exactly that, nobody here is prescribing

🔥1113🧊1

low and slow here means smaller steps than i ever used on tirzepatide, thats the received wisdom, thats just me

SS

stopped for 12 months and restarted at half my old dose, the ramp was easier second time

VV

buying this is a completely different risk conversation from the licensed compounds and that gets said too rarely

*PeptideMeter not the other one

the half life supports weekly dosing and thats what ive done from the start

reconstituted the 2 vial to 2.5mg/ml specifically so i could take 7.5 without measuring crumbs

OO

stepping in 1 increments instead of doubling is the only thing i would change if i started again

HH

i was wrong to call the heart rate a non issue last year, enough people logged it that i changed my mind

HH

quick one TRIUMPH is the phase 3 programme, thats the name to search rather than the molecule

Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.

is the glucagon arm what people mean by the energy expenditure thing

*VendorInvestigate not the other one

OO

i said 7 months ago that my heart rate had settled and it has stayed settled since

HH

genuine question how do people square the research use only framing with logging their own use

OO

why does everyone insist on smaller steps here than on the other two

smaller steps here